1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Audience Unimpressed By Verve’s Base Playing

 
• By Elizabeth Cairns

Verve’s shares dropped hard on its recent Phase I data, and it might be up to Lilly to retore investor confidence.    

Verve Therapeutics

Gene editing, with which Vertex Pharmaceuticals Incorporated has seen success, is one thing; base editing may be another. Shares in Verve Therapeutics, Inc. cratered on the NASDAQ after data presented at the American Heart Association on 12 November revealed that two patients treated with Verve’s base-editing anti-cholesterol therapy VERVE-101 suffered severe cardiovascular events.

Key Takeaways
  • Verve’s first base-editing therapy seems to work in patients with high cholesterol and heart disease

The company’s stock price fell 40% the day after the data were released, opening at $9.50 on 13 November, though...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.